Chinese medical devices major
Mindray Medical International Limited
) recently reported a definitive agreement to takeover ZONARE
Medical Systems, Inc. (ZONARE), for $105 million. ZONARE is a
leader with ultrasound expertise.
Mindray forecasts the acquisition to be mildly dilutive to
earnings in 2013 and 2014. ZONARE generated sales of about $64
million in 2012.
ZONARE was established in 1999 in Mountain View, California.
It operates at the high end of the market worldwide.
Mindray stands to gain from its U.S. based sales setup and
R&D abilities. Synergies are expected from Mindray's
streamlined manufacturing process and ZONARE'S marketing
Mindray plans to keep ZONARE's current operational setup as
well as its existing management structure. The deal is
anticipated to close in the third quarter of 2013 and is subject
to standard regulatory and other clauses.
Mindray is a bellwether in the Chinese MedTech industry with a
solid international presence. A key distinction with domestic
competitors is that the majority of Mindray's products have CE
Mark and/or Food and Drug Administration (FDA) clearance.
Mindray maintains a decent product pipeline and brings out
several new products each year. New products contribute in a
major way to Mindray's revenues. In 2012, the company launched 10
new products and acquired four companies.
The company has entered the premium segment globally, where
its competitive advantage is still unclear. Also, on the negative
side, health care reforms in China and the U.S. may reduce demand
for Mindray's products. Competition is fierce and leads to price
erosion over time.
The stock carrries a Zacks Rank #3 (Hold).
Becton, Dickinson and Company
Heartware International Inc.
Intuitive Surgical, Inc.
) each carry a Zacks Rank #2 (Buy) and are expected to do
BECTON DICKINSO (BDX): Free Stock Analysis
HEARTWARE INTL (HTWR): Free Stock Analysis
INTUITIVE SURG (ISRG): Free Stock Analysis
MINDRAY MEDICAL (MR): Free Stock Analysis
To read this article on Zacks.com click here.